Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 20, 2025

Netflix (NFLX) Down 1.5% Since Last Earnings Report: Can It Rebound?

View original at finance.yahoo.com
Netflix (NFLX) Down 1.5% Since Last Earnings Report: Can It Rebound? It has been about a month since the last earnings report for Netflix (NFLX)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Absent the Brazilian tax expense, Netflix would have exceeded its third-quarter operating margin forecast

    80% confidence

  • Total viewing hours grew faster in the third quarter than in the first half of 2025

    80% confidence

  • Netflix is on track to more than double ad revenues in 2025, albeit from a relatively small base

    80% confidence

  • Netflix does not expect the Brazilian tax matter to have a material impact on future results

    80% confidence

  • These AI advancements will enable Netflix to test, iterate, and innovate on dozens of ad formats by 2026

    80% confidence

  • The earnings shortfall was primarily attributed to a one-time $619 million expense related to an ongoing dispute with Brazilian tax authorities

    80% confidence

  • Netflix has a Zacks Rank #4 (Sell) and analysts expect a below average return from the stock in the next few months

    80% confidence

  • In the fourth quarter, Netflix is using AI to test new ad formats to generate the most relevant ad creative and placement for members, and for faster development of media plans

    80% confidence

  • Netflix achieved its highest quarterly viewing share ever in both the United States and the United Kingdom in Q3 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Netflix (NFLX) Down 1.5% Since Last Earnings Report: Can It Rebound? — Source | Via News | Finance Via News